These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35748739)

  • 1. Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.
    Nair VS; Hui AB; Chabon JJ; Esfahani MS; Stehr H; Nabet BY; Zhou L; Chaudhuri AA; Benson J; Ayers K; Bedi H; Ramsey M; Van Wert R; Antic S; Lui N; Backhus L; Berry M; Sung AW; Massion PP; Shrager JB; Alizadeh AA; Diehn M
    Cancer Res; 2022 Aug; 82(16):2838-2847. PubMed ID: 35748739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
    Sather CL; Yang P; Zhang C; Fitzgibbon MP; Fournier M; Toloza E; Tandon A; Schabath M; Yoder S; Nair VS
    Cancer Med; 2023 Sep; 12(17):17632-17637. PubMed ID: 37587851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
    Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
    Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
    Rolfo C; Malapelle U; Russo A
    Cancer Res; 2022 Aug; 82(16):2826-2828. PubMed ID: 35971678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.
    Nair N; Camacho-Vanegas O; Rykunov D; Dashkoff M; Camacho SC; Schumacher CA; Irish JC; Harkins TT; Freeman E; Garcia I; Pereira E; Kendall S; Belfer R; Kalir T; Sebra R; Reva B; Dottino P; Martignetti JA
    PLoS Med; 2016 Dec; 13(12):e1002206. PubMed ID: 28027320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
    Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
    Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling.
    Bale TA; Yang SR; Solomon JP; Nafa K; Middha S; Casanova J; Sadowska J; Skakodub A; Ahmad H; Yu HA; Riely GJ; Kris MG; Chandarlapaty S; Rosenblum MK; Gavrilovic I; Karajannis MA; Pentsova E; Miller A; Boire A; Mellinghoff I; Berger MF; Zehir A; Ladanyi M; Benayed R; Arcila ME
    J Mol Diagn; 2021 Jun; 23(6):742-752. PubMed ID: 33781965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
    Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.